PMC2796235_01
T1-weighted axial MRI-scan of the brain. T1-weighted axial MRI showed a (sub)occipital right-sided bone defect and a lesion in the right cerebellar hemisphere (a) that enhanced after i.v. Gadolinium administration (b).
CRM2009-757898.001.jpg
PMC2796235_01_CRM2009-757898.001.jpg
fig1
An MRI-scan of the brain (Figures 1(a) and 1(b)) showed a (sub)occipital right-sided bone defect, contiguous to a subcutaneous neurofibroma, and a lesion in the right cerebellar hemisphere that enhanced after Gadolinium administration (Figure 1(b)).
Histopathological and immunohistochemical findings. Histology of the first lesion showed a cellular astrocytic neoplasm (H&E) (a). The second lesion impressed as a neurofibroma (H&E) (b). The first lesion was GFAP positive (c), whereas the second was not (data not shown). This lesion was however positive for S100 (d). ~10%-15% of the nuclei of the first lesion were immunohistochemically stained for Ki-67 (MiB1) (e). In this lesion, approximately 30% of the cells showed immonupositivity for p53 (f).
CRM2009-757898.002.jpg
PMC2796235_01_CRM2009-757898.002.jpg
fig2
Histological analysis revealed two distinct lesions: a mitotically active pleomorphic astrocytoma with pathologic vascular proliferation that was classified as glioblastoma multiforme (astrocytoma, grade 4) (Figures 2(a), 2(c), 2(e), and 2(f)) and a diffuse neurofibroma (Figures 2(b) and 2(d)). On immunohistochemistry, the first lesion was positive for GFAP (Figure 2(c)), the second negative (data not shown), but positive for S100 (Figure 2(d)). Approximately 10%-15% of the nuclei of the first lesion were positive for the proliferation marker Ki67 (MiB1) (Figure 2(e)) and 1% of the nuclei of the neurofibroma (data not shown). 